[Irinotecan as second-line chemotherapy for 5-FU-resistant gastric cancer with disseminated intravascular coagulation: a case report]

Gan To Kagaku Ryoho. 2011 Sep;38(9):1517-20.
[Article in Japanese]

Abstract

A 60-year-old female was diagnosed as advanced gastric cancer with multiple bone, neck and mediastinal lymph node metastases. As a primary chemotherapy, she was treated with S-1(50 m g/body, twice daily for 4 weeks, followed by a 2- week rest). After 3 courses of S-1, she developed a disease progression with pulmonary lymphangitic carcinomatosis and disseminated intravascular coagulation(DIC). Therefore, she received second-line chemotherapy of irinotecan(CPT-11 150 mg/m2, biweekly). Within 3 weeks of starting the treatment, the clinical and laboratory signs of DIC were dramatically resolved. There have been no previous reports of irinotecan alone showing such remarkable effectiveness in a patient with 5- FU-resistant gastric cancer with DIC.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Camptothecin / analogs & derivatives*
  • Camptothecin / therapeutic use
  • Disseminated Intravascular Coagulation / complications*
  • Fatal Outcome
  • Female
  • Fluorouracil / therapeutic use
  • Humans
  • Irinotecan
  • Middle Aged
  • Neoplasm Staging
  • Salvage Therapy*
  • Stomach Neoplasms / complications
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology

Substances

  • Antineoplastic Agents, Phytogenic
  • Irinotecan
  • Fluorouracil
  • Camptothecin